Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. It holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. (a clinical-stage pharmaceutical company), Barer Institute Inc. (a preclinical cancer metabolism research operation), and a majority interest in Cornerstone Pharmaceuticals, Inc. (a cancer metabolism-based therapeutics company). It holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their cannabis offerings enabling them to bring to market predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt. Its investments include Cyclo Therapeutics Inc. (developing Trappsol Cyclo). It holds a portion of a commercial building in Israel.
企業コードRFL
会社名Rafael Holdings Inc
上場日Mar 12, 2018
最高経営責任者「CEO」Mr. Howard S. Jonas
従業員数28
証券種類Ordinary Share
決算期末Mar 12
本社所在地520 Broad Street
都市NEWARK
証券取引所NYSE Consolidated
国United States of America
郵便番号07120
電話番号12126581450
ウェブサイトhttps://rafaelholdings.com
企業コードRFL
上場日Mar 12, 2018
最高経営責任者「CEO」Mr. Howard S. Jonas
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし